Screener
Maravai LifeSciences Holdings, Inc. MRVI Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Maravai LifeSciences Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: Maravai LifeSciences Holdings, Inc.’s 10-Q, filed August 7, 2026. Open the filing →
- Filed
- Aug 7, 2026, 4:03 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001823239-26-000059
FAQ
- What is Maravai LifeSciences Holdings, Inc.'s cash & equivalents?
- Maravai LifeSciences Holdings, Inc. (MRVI) reported cash & equivalents of $70.58M in Q2 2026.
- How has Maravai LifeSciences Holdings, Inc.'s cash & equivalents changed year-over-year?
- Maravai LifeSciences Holdings, Inc.'s cash & equivalents decreased by 73.8% year-over-year, from $269.91M to $70.58M.
- What is the long-term trend for Maravai LifeSciences Holdings, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Maravai LifeSciences Holdings, Inc.'s cash & equivalents has grown at a -1.7% compound annual growth rate (CAGR), from $236.18M to $216.89M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Maravai LifeSciences Holdings, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude